Neal Gregory Spada

Neal Spada practices at UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Neal Spada's NPI, 1639412539, was assigned on March 29, 2013. Neal Spada graduated from University of Pittsburgh School of Medicine in 2013. Neal Spada holds Pennsylvania license MD457325.

Neal Spada's primary practice is UPMC Magee-Womens Hospital, at 300 Halket Street, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 641-4010.

Neal Spada's primary practice is UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Neal Spada is also affiliated with UPMC Presbyterian. The medical group on file is UPMC Hillman Cancer Center. Dmand AI also links Neal Spada to 2 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Neal Spada practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Neal Spada's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Neal Spada is licensed in Pennsylvania.

CMS data shows 1,214 Medicare services from Neal Spada across 9 procedure codes in 2024, for 267 Medicare patients. Medicare paid $86,994 for them.

CMS counts 267 Medicare patients who saw Neal Spada in 2024. The largest group is 65 to 74, with 112 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 2.03, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Neal Spada's median patient age at 74, with 45% women.

In 2024, Neal Spada wrote 1,876 Medicare Part D claims for 289 patients. 75% of them were for generic drugs. CMS names the drug for 1,682 of them, across 43 drugs with 11 or more claims each, at $4,129,839 in total drug cost. In 2023, CMS named 1,169 claims across 34 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 65 out of 100 for Neal Spada for performance year 2024, reported as part of a group. Neal Spada accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Neal Spada as offering telehealth.

Dmand AI links 3 papers to Neal Spada, published from 2017 to 2021. Neal Spada's most frequent co-authors are Emily Muskin Geramita, MD, PhD, Katie S. Nason, MD and Weijing Sun, MD.

CMS Open Payments shows 10 general payments to Neal Spada from 6 drug and device companies from 2018 to 2024. Food and beverage make up the largest share, 79% of the total. AstraZeneca Pharmaceuticals LP paid the most, $595.

Neal Spada graduated from University of Pittsburgh School of Medicine in 2013.